{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"565"}],"units":"Participants"}],"groups":[{"description":"Atezolizumab 1200 mg was administered IV on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurred first.","id":"OG000","title":"Atezolizumab"}],"paramType":"NUMBER","populationDescription":"ATA evaluable population included all participants who received atezolizumab treatment and had at least one post treatment ATA result.","reportingStatus":"POSTED","timeFrame":"Baseline up to approximately 2.25 years (assessed at predose [Hour {Hr} 0] on Day 1 of Cycles 1, 2, 3, 4, 8, 16, then every 8 cycles up to end of treatment (EOT) [approximately 2.25 years]; 120 days after EOT [approximately 2.25 years] [1 Cycle=21 days])","title":"Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) Against Atezolizumab","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}